B. Metzler seel. Sohn & Co. AG Has $11.99 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

B. Metzler seel. Sohn & Co. AG trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 12.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 46,004 shares of the medical research company's stock after selling 6,663 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Amgen were worth $11,990,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Centricity Wealth Management LLC acquired a new position in Amgen during the fourth quarter worth $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the 3rd quarter worth about $29,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the 4th quarter worth about $34,000. Atala Financial Inc bought a new position in Amgen during the 4th quarter valued at about $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen during the 4th quarter valued at about $36,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 1.4 %

Shares of Amgen stock traded up $4.15 during trading hours on Thursday, hitting $309.85. The company's stock had a trading volume of 3,274,556 shares, compared to its average volume of 2,709,297. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a market capitalization of $166.45 billion, a PE ratio of 41.04, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The stock has a 50 day moving average of $303.16 and a 200 day moving average of $297.69.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Bank of America raised their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Johnson Rice set a $294.00 target price on Amgen in a research note on Wednesday, March 5th. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Truist Financial dropped their price objective on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a research report on Wednesday, January 8th. Finally, Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen currently has a consensus rating of "Moderate Buy" and an average target price of $314.04.

Insider Buying and Selling at Amgen

In related news, EVP David M. Reese sold 8,711 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. 0.69% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.